» BiPar Sciences, Inc. Expands Phase 2 <b>Clinical Trials</b> of BSI-201, a <b>...</b>
BRISBANE, Calif., May 8 /PRNewswire/ — BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third…